Purpose of review Evidence-based treatments for prediabetes can prevent and delay the development of type 2 diabetes in adults. In this review, we propose a framework for population-based diabetes prevention that links screening and prevention activities across key stakeholders. We also discuss gaps in current practice, while highlighting opportunities to improve diabetes screening and prevention efforts population-wide. Recent findings Awareness of diabetes risk is low, and many adults with prediabetes are not identified through existing screening efforts. Accumulating evidence and policies support expansion of the Diabetes Prevention Program (DPP) into clinical and community settings. However, the infrastructure to facilitate referrals and promote data exchange among patients, clinical settings, and community-based DPP programs is lacking. Summary Development of evidence-driven, scalable processes for assessing diabetes risk, screening eligible adults, and delivering preventive treatments are needed to effectively improve the glycemic health of the US adult population.
Introduction
More than 30 million US adults have type 2 diabetes (T2D), exacting a large public health and economic toll that is steadily increasing as the US population ages [1] . The individual burden of diabetes self-management and treatment is significant, making the prevention or delay of T2D critical for both patients and populations. Recent clinical innovations and interventions have had a large collective impact on the prevalence of complications and life expectancy of patients with diabetes [2] . Part of this success stems from earlier diagnosis and treatment, which appears to have long-lasting effects on the pathophysiology and clinical course of diabetes [3] . In spite of these advances, significant work remains to optimize the glycemic health and health outcomes across the US adult population. Achieving this vision will require coordinated efforts across public health, community, and healthcare settings.
Primary prevention of T2D is critical to curbing the individual, population, and economic toll of T2D. Diabetes risk increases across the glycemic spectrum, making it possible to identify individuals at high risk for diabetes years before they develop clinically apparent T2D. Thus, risk assessment and screening play an important role in curbing the development of T2D. Although clinicians screen for T2D, test results are far more likely to identify individuals with prediabetes, which is a high-risk state for developing T2D. Prediabetes is defined by glycemic markers that are above the normal range but below the diagnostic thresholds for diabetes. In the USA, 86 million adults have prediabetes [1] , which confers a 5-10% annual risk and up to a 70% lifetime risk of developing T2D [4, 5, 6 ••]. Alarmingly, 90% of individuals with prediabetes are unaware of their diagnosis highlighting an urgent need for scalable risk assessment and screening strategies [7] .
Intensive lifestyle interventions can delay or prevent diabetes in individuals with prediabetes [8, 9, 10••, 11] . This has been shown in multiple, large clinical trials including the US Diabetes Prevention Program (DPP) which demonstrated a 58% reduction in the incidence of diabetes with a lifestyle intervention focused on weight loss and physical activity [10••] . Long-term follow-up studies of the DPP and similar intensive lifestyle interventions have demonstrated sustained reductions in diabetes incidence, diabetes complications, cardiovascular mortality, and all-cause mortality [12, 13••, 14-16] . Importantly, the DPP lifestyle intervention is costeffective among those with prediabetes, which supports its role in helping stem the diabetes epidemic across the US population [17] . The same clinical trial also demonstrated that metformin can prevent or delay the onset of diabetes in adults with prediabetes, although to a lesser extent than intensive lifestyle interventions. Long-term studies of metformin have reported durable reductions in the risk of developing diabetes; however, they have not yet shown significant improvements in complication rates or mortality [16] . Preventing diabetes at the population level requires the development of scalable and sustainable approaches to assess diabetes risk, screen those at high risk, and deliver evidencesupported interventions to high-risk individuals. Populationbased diabetes prevention also requires policy changes to improve social determinants of health, such as the quality of the food supply, built environment, and transportation systems. Although challenging, systematic implementation of policy changes in these critical areas could have a broad impact and potentially lower diabetes risk across the entire population. Additionally, public health policies that promote health in communities could augment the effects of evidence-based diabetes prevention efforts targeted toward those at high risk. To improve the reach of evidence-based prevention strategies, coordination of diabetes screening and prevention services across clinical practices, health systems, and community organizations is needed.
The purpose of this paper is to review population-based diabetes screening and prevention efforts among US adults to achieve the following objectives: (1) introduce a conceptual framework linking diabetes screening and prevention, (2) highlight examples of these activities conducted at a population level by various stakeholders, and (3) explore gaps in current practice and highlight future directions for improving population-level diabetes screening and prevention.
Population-Based Diabetes Screening and Prevention Framework
Successful population-based diabetes screening and prevention strategies require coordinating activities across different stakeholders in both clinical and community settings. Examples of these stakeholder groups and their potential actions are provided in Table 1 . Individuals, health professionals, healthcare systems, health payers, community organizations, and public health agencies are collectively responsible for assessing diabetes risk, ordering screening tests, managing screening test results, and engaging in preventive treatments. We propose a model of population-based diabetes prevention ( Fig. 1 ) that includes each of these care processes and illustrates recommended actions across each domain. We utilize Fig. 1 as an organizing framework for discussing processes of care (i.e., diabetes risk assessment, diabetes screening, and treatment of prediabetes), followed by a discussion of how these processes have been implemented in population health practice by different stakeholders. Diagnosing diabetes represents the final step in our model, after which individuals require evidence-based interventions for diabetes care that are beyond the scope of this review.
Diabetes Risk Assessment: Identifying High-Risk Individuals for Screening
Assessing an individual's risk of diabetes is critical to determining whether or not a screening test is indicated. Risk assessment utilizes epidemiologic risk factors for developing diabetes, including age, minority race/ethnicity, family history of diabetes, physical inactivity, and metabolic conditions such as overweight/obesity, dyslipidemia, hypertension, gestational diabetes, and polycystic ovarian syndrome [19•, 20] . These and other risk factors form the basis for two common risk assessment strategies: diabetes screening guidelines and diabetes risk scores.
Diabetes screening guidelines utilize patient-or clinician-identified risk factors to determine who should receive a screening test. The most common US screening guidelines are the American Diabetes Association (ADA), American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology (ACE), the US Preventive [21] [22] [23] . These guidelines recommend screening based on a single "test-no test" decision threshold. Differences in how each guideline defines "high risk" substantially impact the number of individuals eligible for screening. Further, the different risk factors included in each screening recommendation produce tradeoffs in their sensitivity and specificity for identifying adults with prediabetes or undiagnosed diabetes [24••] . Diabetes risk scores utilize risk factors to assign a point value based on the presence of risk factors or specific levels of the risk factors (e.g., body mass index). Unlike screening guidelines, risk scores quantify diabetes risk across a range of disease probabilities, allowing users the flexibility to select different testing thresholds depending on the clinical context and their preferences regarding sensitivity and specificity [25] . Table 2 provides examples of existing diabetes risk scores and screening guidelines, including available evidence on the performance characteristics using US population data. [26, 28] . Those with elevated risk scores are advised to contact their healthcare provider for a diabetes screening test and/or enroll in an evidence-based diabetes prevention program. Although the uptake of these risk scores in community settings is unknown, their use in clinical practice is low [39] . This may, in part, reflect challenges of automating these tools within electronic health records (EHRs) due to risk factors that are not systematically captured in structured data fields (e.g., physical activity) [40] .
Population-Based Application of Diabetes Risk Assessment: Challenges and Limitations

Current Gaps and Ongoing/Future Work: EHR-Based Risk Assessment
Risk scores designed to use clinical data from the EHR are uncommon. However, the derivation and validation of diabetes risk scores in clinical populations using EHR data represents an opportunity to efficiently scale risk assessment to While widely recommended by expert groups, systematic, population-based screening and treatment of adults at high risk for diabetes has not been shown to reduce mortality in clinical trials when compared to routine screening and treatment in clinical practice [48] . This is in part explained by advances in cardiovascular risk reduction that have significant mortality benefits in individuals with and without diabetes. Given the low risk of testing, high prevalence of diabetes, and high complication rates and associated costs, some may argue that screening all adults seems reasonable. Furthermore, targeted screening may miss an important population of patients who could benefit from risk reduction counseling and prediabetes treatment. However, universal diabetes screening is not recommended given the lack of data demonstrating a mortality benefit [19•, 20, 48] . Using mortality reduction as the "gold standard" to evaluate screening approaches neglects intermediate micro-and macrovascular complications of T2D that adversely impact patients' quality of life and raise mortality risk, while imposing significant healthcare costs.
In the absence of universal screening, diabetes and prediabetes detection depends on case-finding or opportunistic screening, which is the ordering of screening tests when individuals present to the healthcare system for reasons unrelated to screening [49] . Slightly more than half of all adult patients complete gold-standard diabetes screening tests in clinical practice; however, many high-risk individuals are missed despite having opportunities for screening during healthcare encounters [42•] . Reflex diabetes screening in response to elevated random blood glucose levels may improve case detection. Additional improvements in screening rates may be achieved by coupling diabetes screening with existing clinical workflows for cholesterol screening. This may enhance uptake since cholesterol screening is widely performed in clinical practice. Further research comparing the effectiveness (i.e., diagnostic yield), reach (i.e., test completion), and costs of targeted, opportunistic screening versus "pragmatic" population screening is needed.
Population-Based Application of Diabetes Screening: Challenges and Limitations
Scaling evidence-based diabetes screening and case-finding strategies is critical to diagnosing the 7.2 million US adults with undiagnosed T2D and the 77.4 million US adults with undiagnosed prediabetes [1]. Uptake of screening guidelines is hindered by having multiple recommendations that each include different risk factors. In practice, healthcare providers may find it difficult to make informed decisions about which guideline they should follow, or even remember the corresponding risk factors. These barriers highlight the need for health system interventions to promote widespread adoption of evidence-based diabetes screening guidelines across the clinical populations they serve. Examples may include diabetes screening policies endorsed by health systems that are supported by electronic clinical decision support tools or automated order functionality.
Reimbursement for diabetes screening is critical to supporting and scaling population-level strategies to prevent diabetes. The Affordable Care Act (ACA) requires payers to fully cover USPSTF-recommended preventive services, such as screening guidelines. Although this represents an important step in expanding access to diabetes screening, the 2015 USPSTF guideline narrowly defines risk using age and BMI alone ( Table 2 ). The same guideline suggests that clinicians consider performing a screening test for patients with minority race/ethnicity or other risk factors; however, these indications for screening may not be covered by insurers [21] . Additionally, Medicare does not cover hemoglobin A1c as a diabetes screening test, even though it is considered an eligibility criterion for Medicare to reimburse delivery of the DPP. Expansion of screening guidelines and insurance coverage for screening tests remain opportunities to improve alignment between evidence and practice [21] .
Current Gaps and Ongoing/Future Work: New Opportunities for Diabetes Screening
Point-of-care devices (POC) to measure hemoglobin A1c represent a potential opportunity to scale and expand the reach of population-based diabetes screening efforts. These benchtop instruments enable hemoglobin A1c measurement in either community settings or clinics, where they are frequently used for clinical decision-making in patients with known diabetes. There are many POC devices on the market, but concerns about their accuracy and precision have hindered their use for screening. However, recent research suggests that at least two of these POC instruments meet the widely accepted perf o r m a n c e c r i t e r i a e s t a b l i s h e d b y t h e N a t i o n a l Glycohemoglobin Standardization Program [22, 23] . Some recent evidence suggests that using POC A1c analyzers for diabetes screening in primary care clinics may increase identification of prediabetes and diabetes compared to usual care [50] . Expansion of POC devices for diabetes screening in dental offices, pharmacies, and community-based settings are promising, but require clear instructions about follow-up procedures and linkage to clinical care for those who require repeat testing or treatment [51, 52] . The endorsement of ambulatory blood pressure measurement in the USPSTF hypertension screening guideline suggests the potential for a similar community-based approach in diabetes screening [53•, 54] .
Treatments to Prevent Diabetes
Intensive Lifestyle Interventions
Intensive lifestyle interventions are the most effective treatment to prevent or delay the onset of T2D. The most widely studied of these, the Diabetes Prevention Program (DPP), is a goal-based diet and physical activity intervention that encourages 150 min per week of moderate physical activity and 7% weight loss from baseline. The DPP is most often delivered by lay lifestyle coaches during an in-person, group-based setting over at least 1 year of active intervention. A large number of studies have implemented the DPP in diverse clinical and community-based settings (e.g., YMCAs, churches, nonprofit organizations, employer groups), with meta-analyses demonstrating significant weight loss and associated cardiometabolic improvements [55] [56] [57] [58] . There are also studies testing delivery of the DPP via telephone and web-based applications, which have achieved similar outcomes [59] [60] [61] [62] [63] .
While the DPP has the largest evidence base supporting its effectiveness, other intensive lifestyle programs may also reduce the risk of developing diabetes among high-risk adults. The USPSTF recommends behavioral counseling to promote a healthful diet and physical activity among overweight or obese adults who have other cardiovascular risk factors such as prediabetes [64] . While DPP was cited in this recommendation as an exemplar lifestyle intervention, the USPSTF recommendation is based on a review of many intensive behavioral counseling programs that included at least five contacts over a minimum of nine months [64] . For example, many commercial weight loss programs are similar in intensity to the DPP and rely on evidence-based behavioral strategies utilized in the DPP, such as goal setting, stimulus control, and self-monitoring [65] . One recent study tested the effectiveness of a modified Weight Watchers program for adults with prediabetes and demonstrated a 5.5% weight loss from baseline to 12 months [66] . With their widespread availability and options for digital delivery, commercial weight loss programs offer another promising community-based opportunity to scale diabetes prevention efforts.
Population-Based Delivery of Intensive Lifestyle Interventions
In 2010, Congress authorized the CDC to establish the National Diabetes Prevention Program (NDPP), which supports workforce development and a recognition program for organizations that deliver DPP effectively and with fidelity to the evidencesupported intervention [67] . Initial efforts to develop a national network of DPP delivery sites involved a public-private partnership between CDC, YMCA, and UnitedHealth Group, which scaled DPP programs in YMCAs across 23 US states [68] . There are currently over 1700 programs recognized by the CDC, and the YMCA remains the largest delivery site with more than 200 participating locations [69, 70] . A recent study reported aggregate outcomes from the first 4 years of the NDPP program, which were comparable to those achieved in individual community-based studies of DPP. From 2012 to 2016, the NDPP enrolled 14,747 adults whose mean weight loss was 4.2% from baseline to the completion of the year-long program [71•] . In addition to these national efforts, some US states have also developed DPP programs. For example, the Montana Cardiovascular Disease and Diabetes Prevention Program reported delivering DPP in 16 sites, achieving a mean weight loss of 6.2 kg among almost 4000 participants between 2008 and 2012 [63, 72, 73] .
Large health systems have also developed resources to prevent diabetes across the clinical populations they serve. Recently, the Veterans Health Administration (VHA), the nation's largest integrated health system, adapted its MOVE! Weight Management Program for Veterans to incorporate core design features of the DPP (e.g., 16 sessions comprised of a closed group of participants and a consistent facilitator) [74] . MOVE! remains available to all Veterans who are patients of the VHA and want to lose weight, irrespective of whether they have prediabetes. In addition, AllianceChicago, a national network of federally qualified health centers with a shared, centrally hosted EHR platform has developed customized EHR tools to support DPP delivery across its clinics. These EHR tools help (1) identify patients who are eligible to participate, (2) track attendance and weight measurement during sessions, and (3) generate automated reports required by the CDC to maintain NDPP recognition status. Together, these experiences suggest the potential for population-based effectiveness of the DPP, and the feasibility of strategies to broaden its reach within health systems. Medicare reimbursement for DPP, which began in early 2018, may enhance widespread dissemination of DPP by providing a potentially sustainable funding stream to support the program's delivery.
Metformin and Other Medications
Metformin has demonstrated durable efficacy in reducing diabetes risk among adults with prediabetes in clinical trials [13••, 16] . The efficacy of metformin is greatest in patients with the following demographic and clinical characteristics: ≤ 45 years old, African American race, prior history of gestational diabetes, body mass index ≥ 35 kg/m 2 , and fasting glucose 110-125 mg/dL [10••] . This evidence suggests that metformin may be a useful adjunct to lifestyle change in at least some patient groups, or an effective stand-alone treatment for those not interested in lifestyle change. However, metformin is underutilized for diabetes prevention in routine care, with prescribing estimates ranging from < 0.1 to 3.7% of patients with prediabetes [75, 76••, 77] . Although randomized trials of other antidiabetic medications for diabetes prevention have reported mixed results on diabetes risk reduction, they are not recommended or routinely prescribed to prevent or delay diabetes.
Current Gaps and Ongoing/Future Work: Towards an Integrated Approach
Achieving the goal of population-based diabetes prevention will require a robust referral system linking adults with prediabetes to evidence-supported lifestyle interventions. Not all eligible adults will be able to enroll in NDPP programs because of competing personal demands and limited capacity of current NDPP infrastructure. Adults with elevated diabetes risk who are interested in NDPP programs can refer themselves or receive referrals from their healthcare providers to community-based healthy lifestyle programs following diagnosis of prediabetes. However, these referral strategies rely on individuals' having knowledge of their glycemic status and local prevention programs, both of which are likely limited. Community-based programs are dynamic, and maintaining up-to-date knowledge of available programs is challenging for community members and healthcare providers alike. Further investment and research on community-based options for patient-centered weight loss, nutrition, and physical activity programs are needed to maximize the treatment of prediabetes [78] .
Community-based organizations face multiple challenges in delivering the NDPP. Staff training is coordinated by CDC and a small number of other national partners, who have created a centralized training infrastructure to help maintain fidelity to the evidence-supported intervention. Community organizations are responsible for collecting and reporting the data required to receive and maintain certification through the NDPP recognition program; however, they often have limited expertise, infrastructure, and capacity to support these processes. They also have little or no experience billing Medicare and other payers for services delivered, which may impact the long-term sustainability of programs. Additionally, community-based organizations are challenged to identify eligible participants because they lack access to health records, and community members are often unaware of their elevated diabetes risk [7] .
These challenges highlight an urgent need for expanded infrastructure and policies to promote data exchange between patients, healthcare settings, and community-based providers while supporting DPP delivery and reimbursement [79] . Development of data sharing agreements and platforms supporting secure data exchange between community programs, health systems, and participants are needed to streamline DPP referrals and reporting of outcomes. Clinical decision support provides one potential strategy to facilitate curation of available prevention programs and automate referrals between clinics, where individuals are identified as having prediabetes, and DPP delivery sites in both clinical and community settings. This EHR-based strategy could also promote prescribing of metformin for treatment of prediabetes. Data linkages between organizations delivering the DPP and the healthcare system are critical for research on the long-term health outcomes and impact of DPP participation. Studies testing the effectiveness of clinical decision support as a clinic-based strategy for adopting treatments to prevent diabetes are currently underway.
Third-party administrators focused on disease prevention are beginning to link patients, payors, and physicians with organizations delivering the DPP, and continued growth in this space is likely to play an important role in expanding the reach of the DPP. Data sharing across compatible platforms could support an expanded role for third-party administrators in coordinating DPP referrals across multiple clinical systems, health departments, employers, community-based organizations, and individuals seeking DPP programs. Further research is needed on the role of advanced payment models to fund community DPP delivery by encouraging payers to enter formal partnerships with health systems and manage the glycemic risk of populations through health promotion and disease prevention.
Our findings in this paper and recommendations for future research should be considered in the context of international efforts in diabetes screening and prevention, employer-based programs, policy-based programs impacting diabetes prevention at the population level, and management of T2D. These topics have been reviewed elsewhere and complement our current focus on population-based approaches to diabetes screening and prevention in the U.S. 
Conclusions
Like most chronic diseases, individuals develop T2D as a result of the complex interaction between biologic and behavioral risk factors. Public health interventions and changes to the built environment are critical to building sustainable efforts to prevent diabetes. Opportunities to target diabetes prevention interventions to high-risk individuals occur when these individuals interface with community and clinical settings. Successful management of glycemic risk within and across populations requires structured processes and coordination of care to deliver risk assessment, screening, and interventions across settings. Coordinated approaches to diabetes prevention may help organize and scale existing efforts that span clinical and community settings.
Until there are effective and sustainable policies to address the burden of diabetes for the entire adult population, prevention efforts should focus on coordinated action across multiple stakeholders and venues to ensure that high-risk individuals are identified, offered appropriate treatment, and followed longitudinally. Future work in this area requires technological infrastructure that operates across these settings to help link eligible individuals with evidence-based lifestyle programs and/or metformin. At the same time, healthcare providers, health systems, payers, and public health agencies have a shared responsibility to support high-risk individuals and facilitate patient-centered decisions about assessing their diabetes risk, undergoing screening, and choosing treatment. Future research will help evaluate and refine these ongoing efforts.
